+91-8668442535

Vasculitis Treatment Market By Drug Class (Biologics, Corticosteroids and Immunosuppressant), By Disease Condition (Large Vessel Vasculitis, Medium Vessel Vasculitis and Small Vessel Vasculitis) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

The vasculitis treatment market is expected to reach US$ 601.2 million by 2026, up from US$ 365.1 million in 2017, with a consistent compound annual growth rate (CAGR) of 5.7% from 2018 to 2026. According to the Vasculitis Foundation's 2016 report, the global prevalence of vasculitis is 1-9 per 100,000 people. Vasculitis shows a high degree of incidence in the Caucasian population and is widely prevalent in the Scandinavian countries. Earlier, cyclophosphamide was considered the first line of treatment for all types of vasculitis. In 2010, the United States Food and Drug Administration (USFDA) approved rituximab for the treatment of vasculitis along with prednisolone. Pharmaceutical and biotechnology industries are constantly striving to achieve a targeted drug therapy approach for the treatment of vasculitis, majorly focusing on monoclonal antibodies such as tocilizumab, mepolizumab, and infliximab. CCX168, developed by ChemoCentryx and currently under phase II clinical trials, is an immunosuppressant projected to enter the market by 2021 and is anticipated to register impressive growth during the forecast period for the treatment of ANCA-associated vasculitis. In 2017, North America held the largest market share in the vasculitis treatment market on account of the developed healthcare infrastructure and increased public health awareness that resulted in early vasculitis diagnosis. North America is the domicile of key players engaged in the treatment of vasculitis disease, which contributes to its dominance in this market. Asia Pacific will register significant growth during the forecast period owing to a huge geriatric population suffering from large vessel vasculitis and a supportive regulatory environment for the treatment of vasculitis disease.

Market Synopsis

Better Clinical Outcomes in Vasculitis Treatment Will Contribute to the Biologics Segment Growth

Currently, biologics are leading the market by drug class segment and will continue to showcase excellent growth during the forecast period. In 2010, the USFDA gave approval to rituximab for the treatment of vasculitis disease in combination with prednisolone. The dosage regimen currently postulated for rituximab throughout the globe is the 4+2 protocol. Because of improved drug safety and efficacy, as well as the rising prevalence of antineutrophil cytoplasmic autoantibodies (ANCA) associated renal vasculitis in the elderly population, biologics accounted for 38.98% of the drug class segment's share in 2017. The only limitation of using rituximab therapy is its high cost, which hinders treatment in poor nations. Cyclophosphamide is used in patients showing resistance to rituximab therapy, and its relatively low treatment cost contributes to its market growth in developing nations.

Accurate Diagnosis of Small Vessel Vasculitis is Expected to Have the Highest Double-Digit CAGR During the Forecast Period

The challenge that usually occurs during the diagnosis of vasculitis is its overlapping symptoms with those of other inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, etc. Because of the non-specificity of serological markers and irrational tissue biopsy, there is ambiguity. Leucocytes are the primary inflammatory mediators that occur at the onset of vasculitis. The factors responsible for the accurate diagnosis of vasculitis are the technological advancement in diagnostic kits and the availability of skilled workers to perform the diagnosis. In 2017, large vessel vasculitis occupied 45% of the overall vasculitis disease epidemiology. The key attributes favoring the dominance of large vessel vasculitis are the rising prevalence of immunocompromised patients and medicine-related adverse events encountered in Caucasian populations. Small vessel vasculitis will showcase impressive growth during the forecast period owing to the increasing number of blood vessel aneurysm cases encountered in the Mongolian population and the rampant growth in the reported cases of small vessel vasculitis initiated due to pesticide and chemical exposure.

Raising public health awareness in Asia-Pacific will pave the way for rapid growth during the forecast period.

In 2017, North America occupied 35.96% of the global market share for vasculitis treatment. The key factors responsible for the North American market's growth are the rising prevalence of large vessel vasculitis, the presence of key players such as Bristol-Myers Squibb Company, Celgene Corporation, etc., and the existence of advanced healthcare facilities. Asia Pacific will be the fastest-growing market on account of a large geriatric population suffering from small vessel vasculitis, enhanced funding by pharmaceutical companies in the R&D segment, and rising public health awareness resulting in early diagnosis and treatment.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The Vasculitis Treatment Market Report provides quantitative analysis as well as the most recent market trends. The market is segmented by drug class, disease condition, and geography.

A market assessment is performed in order to understand the prevailing market trends in the vasculitis treatment market. The market estimation is done by providing the compounded annual growth rate (CAGR) and data forecast for 2018–2026. The product portfolio is helpful in giving information on the FDA-approved drugs currently prescribed for the treatment of vasculitis disease. Strategic collaboration, mergers, and acquisitions among the key players for developing an impressive product pipeline are mentioned in the business strategy section. The key players currently engaged in the vasculitis treatment market are F. Hoffmann-La Roche Ltd., AstraZeneca, Baxter International, Bristol-Myers Squibb Company, Celgene Corporation, ChemoCentryx, Daiichi Sankyo, Eli Lilly & Company, GlaxoSmithKline Plc, Merck & Co., and Novartis AG.

Key questions are answered in this report.

  • How will the global vasculitis treatment market perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the vasculitis treatment market and the most valuable opportunities for the key players?
  • Who is the leading player in the global vasculitis treatment market?
  • Which is the leading and fastest-growing region in the global vasculitis treatment market?
  • What are the methods of diagnosis employed for the confirmation of vasculitis disease?
  • Currently, what are the treatment guidelines used for the management and treatment of vasculitis disease?
  • What impact would the pipeline drugs have on the global vasculitis treatment market?
  • What are the drivers and restraints governing the global vasculitis treatment market?

Frequently Asked Questions:

The market for Vasculitis Treatment is expected to reach US$ XX Mn in 2026.

The Vasculitis Treatment market is expected to see significant CAGR growth over the coming years,at 5.7%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

F.Hoffman La Roche Ltd.,AstraZeneca,Baxter International,Bristol Myers Squibb Company,Celgene Corporaion are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  May 2018
Category:  Pharmaceuticals
Report ID:   59143
Report Format:   PDF
Pages:   120
Rating:    4.2 (40)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support